Every
Regulatory strategy,
clinical technology,
and
market access
under one roof,
built for approvals and outcomes rather than slide decks.
FDA
EMA
MHRA
PMDA
Swissmedic
Health Canada
TGA
ANVISA
Every engagement begins with one honest question.
No pitch decks, no junior hand-offs. Before we propose anything, a partner sits with your team, finds the decision that matters most — and builds the evidence around it.
Hypotheses become protocols
Protocols become evidence
Evidence becomes approval
Approval becomes access
Access becomes outcomes
Six disciplines. One standard of evidence.
Where science, regulation and markets finally meet.
Scientific depth
Partners with MD, PhD and PharmD backgrounds who read the data themselves — not through a slide deck.
Regulatory fluency
Former agency reviewers and notified-body assessors who know how decisions are actually made.
Technology & AI
Data scientists and engineers who validate algorithms, models and digital endpoints to clinical standard.
Wherever evidence decides, we are in the room.
Turning insight into structured execution.
01
Diagnose
We interrogate the data, the plan and the people to find the one decision that changes the outcome.
02
Design
Options are modelled against evidence, cost and time — then stress-tested with expert panels.
03
Deliver
Partners stay hands-on through submissions, agency meetings and board reviews.
04
Sustain
Clear milestones, monthly read-outs and a team that remains on call as the science evolves.
Agency interactions prepared
Transactions advised on
Programmes delivered on time
Specialists in our expert network
Why not simply hire a larger firm?
Typical approach
Generalist teams rotated across industries
Slide-heavy reports, weeks after the decision
Junior analysts do most of the work
Advice independent of regulators’ reality
Hourly billing with open-ended scope
Illuminate
Clinicians, scientists and ex-regulators only
Decision memos timed to your governance calendar
Partners stay hands-on from first call to filing
Mock panels with former agency reviewers
Fixed fees against defined deliverables
What leadership teams tell us afterwards.
The rare advisor who is equally comfortable in front of an agency panel and inside a data room. Every recommendation came with the evidence behind it.
Dr. Lena Brandt
They spoke fluent machine learning and fluent FDA. Our clearance came months earlier than our own plan assumed.
Tomas Riedel
Calm, precise and unusually honest. They told us what we needed to hear, not what we wanted to hear — and that saved the programme.
Priya Raman
For the first time our digital programme was evaluated with the same rigour as a new drug. The board noticed.
Dr. Ana Kovač
Their investment memo was the one document our committee actually read cover to cover.
Olivia Hart
Notes for sharper scientific decisions.
Questions? We’re glad you asked.
With a 45-minute briefing call under NDA. Within five working days we send a short proposal with scope, team, timeline and a fixed fee — no lengthy pitch process.
Yes. Roughly a third of our clients are pre-clinical or Phase I biotechs and medtech start-ups. We offer focused sprints designed for seed and Series A budgets.
Most projects are fixed-fee against clearly defined deliverables. For longer programmes we offer monthly retainers with a capped number of partner days.
The partners you meet are the partners you work with. Every engagement is led by a senior partner and supported by specialists — we never hand off to junior teams.
Oncology, cardiometabolic, neuroscience, rare disease and infectious disease, as well as diagnostics, imaging and digital health. Our network of 300+ experts covers niche indications on request.
We prepare briefing packages, rehearse with mock panels and can attend meetings alongside your team. The sponsor always remains the formal applicant.










